A meta-analysis of thirteen studies with more than 500,000 people, published Oct. 28, 2026, in Dermatologic Surgery, found that Mohs surgery for melanoma was linked to similar or better long-term survival than wide local excision, especially for head and neck…
Five-year results of the RELATIVITY-047 trial, published Oct. 24, 2026, in Nature Medicine, show that relatlimab plus nivolumab kept improving survival in advanced melanoma compared with nivolumab alone (hazard ratio for death 0.78).
In a phase 2 study published Oct. 28, 2026, in the Journal of Clinical Oncology, 44 previously untreated people with metastatic uveal melanoma took darovasertib plus crizotinib. Tumors shrank in 34.1%, and median overall survival was 21.1 months.